Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells

Wang,Xiaofeng; He,Jinting; Zhao,Xiaoming; Qi,Tianyang; Zhang,Tianfu; Kong,Chenfei

doi:10.3892/or.2018.6271

Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells

Authors:
- Xiaofeng Wang
- Jinting He
- Xiaoming Zhao
- Tianyang Qi
- Tianfu Zhang
- Chenfei Kong
View Affiliations

Affiliations: Department of Stomatology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Scientific Research Center, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: February 14, 2018 https://doi.org/10.3892/or.2018.6271
Pages: 1835-1842

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial-mesenchymal transition (EMT) is one of the major processes that contribute to the occurrence of cancer metastasis. EMT has been associated with the development of oral cancer. Syndecan‑1 (SDC1) is a key cell‑surface adhesion molecule and its expression level inversely correlates with tumor differentiation and prognosis. In the present study, we aimed to determine the role of SDC1 in oral cancer progression and investigate the molecular mechanisms through which SDC1 regulates the EMT and invasiveness of oral cancer cells. We demonstrated that basal SDC1 expression levels were lower in four oral cancer cell lines (KB, Tca8113, ACC2 and CAL‑27), than in normal human periodontal ligament fibroblasts. Ectopic overexpression of SDC1 resulted in morphological transformation, decreased expression of EMT‑associated markers, as well as decreased migration, invasiveness and proliferation of oral cancer cells. In contrast, downregulation of the expression of SDC1 caused the opposite results. Furthermore, the knockdown of endogenous SDC1 activated the extracellular signal‑regulated kinase (ERK) cascade, upregulated the expression of Snail and inhibited the expression of E‑cadherin. In conclusion, our findings revealed that SDC1 suppressed EMT via the modulation of the ERK signaling pathway that, in turn, negatively affected the invasiveness of human oral cancer cells. Our results provided useful evidence about the potential use of SDC1 as a molecular target for therapeutic interventions in human oral cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wang B, Zhang S, Yue K and Wang XD: The recurrence and survival of oral squamous cell carcinoma: A report of 275 cases. Chin J Cancer. 32:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
3	Exarchos KP, Goletsis Y, Poli T and Fotiadis DI: Gene expression profiling towards the prediction of oral cancer reoccurrence. Conf Proc IEEE Eng Med Biol Soc. 2011:pp. 8307–8310. 2011; PubMed/NCBI
4	Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W and Mao L: Gene expression profiling predicts the development of oral cancer. Cancer Prev Res. 4:218–229. 2011. View Article : Google Scholar
5	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
6	Thiery JP: Epithelial-mesenchymal transitions in cancer onset and progression. Bull Acad Natl Med. 193:1969–1979. 2009.(In French). PubMed/NCBI
7	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
8	David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA and Massagué J: TGF-beta Tumor suppression through a Lethal EMT. Cell. 164:1015–1030. 2016. View Article : Google Scholar : PubMed/NCBI
9	Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhou J, Jain S, Azad AK, Xu X, Yu HC, Xu Z, Godbout R and Fu Y: Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells. Cell Signal. 28:838–849. 2016. View Article : Google Scholar : PubMed/NCBI
11	Kong C, Wang C, Wang L, Ma M, Niu C, Sun X, Du J, Dong Z, Zhu S, Lu J and Huang B: NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 6:e226662011. View Article : Google Scholar : PubMed/NCBI
12	Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shih JY and Yang PC: The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011. View Article : Google Scholar : PubMed/NCBI
14	Harada K, Masuda S, Hirano M and Nakanuma Y: Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 34:857–863. 2003. View Article : Google Scholar : PubMed/NCBI
15	Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K and Sanderson RD: Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem. 284:26085–26095. 2009. View Article : Google Scholar : PubMed/NCBI
16	Anttonen A, Kajanti M, Heikkilä P, Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 79:558–564. 1999. View Article : Google Scholar : PubMed/NCBI
17	Maeda T, Alexander CM and Friedl A: Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 64:612–621. 2004. View Article : Google Scholar : PubMed/NCBI
18	Guo Q, Yang X, Ma Y and Ma L: Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 36:506–513. 2015.PubMed/NCBI
19	Giordano RJ: Heparanase-2 and syndecan-1 in colon cancer: The ugly ducklings or the beautiful swans? Eur J Gastroenterol Hepatol. 20:716–718. 2008.PubMed/NCBI
20	Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ and Kim HR: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: A role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer. 85:176–181. 2000. View Article : Google Scholar : PubMed/NCBI
21	Hsu YL, Hou MF, Kuo PL, Huang YF and Tsai EM: Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway. Oncogene. 32:4436–4447. 2013. View Article : Google Scholar : PubMed/NCBI
22	Li S, Lu J, Chen Y, Xiong N, Li L, Zhang J, Yang H, Wu C, Zeng H and Liu Y: MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol Immunol. 14:621–630. 2017. View Article : Google Scholar : PubMed/NCBI
23	Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Takamori K, Igawa K, Yoshida M, Fukuyama H, Takahashi T and Sakoda S: Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma. J Oral Pathol Med. 35:301–306. 2006. View Article : Google Scholar : PubMed/NCBI
24	Muramatsu T, Saitoh M, Ro Y, Uekusa T, Iwamura E, Ohta K, Kohno Y, Abiko Y and Shimono M: Inhibition of syndecan-1 expression and function in oral cancer cells. Oncol Rep. 20:1353–1357. 2008.PubMed/NCBI
25	Patel S, Shah K, Mirza S, Daga A and Rawal R: Epigenetic regulators governing cancer stem cells and epithelial-mesenchymal transition in oral squamous cell carcinoma. Curr Stem Cell Res Ther. 10:140–152. 2015. View Article : Google Scholar : PubMed/NCBI
26	Vered M, Dayan D, Yahalom R, Dobriyan A, Barshack I, Bello IO, Kantola S and Salo T: Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int J Cancer. 127:1356–1362. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang YC, Lu SW, Yu CH, Huang HS, Wang JJ, Tsai CH, et al: Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep. 26:1003–1010. 2011.PubMed/NCBI
28	Leppä S, Vleminckx K, Van Roy F and Jalkanen M: Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent. J Cell Sci. 109:1393–1403. 1996.PubMed/NCBI
29	Sun D, McAlmon KR, Davies JA, Bernfield M and Hay ED: Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation. Int J Dev Biol. 42:733–736. 1998.PubMed/NCBI
30	Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M and Lupo A: Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem. 287:1478–1488. 2012. View Article : Google Scholar : PubMed/NCBI
31	Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P, Gallegos I, Morales B, Huidobro C and Castellón EA: The expression of syndecan-1 and −2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol. 28:534–540. 2010. View Article : Google Scholar : PubMed/NCBI
32	Poblete CE, Fulla J, Gallardo M, Muñoz V, Castellón EA, Gallegos I and Contreras HR: Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer. Int J Oncol. 44:647–654. 2014. View Article : Google Scholar : PubMed/NCBI
33	Heidari-Hamedani G, Vivès RR, Seffouh A, Afratis NA, Oosterhof A, van Kuppevelt TH, Karamanos NK, Metintas M, Hjerpe A, Dobra K and Szatmári T: Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma. Cell Signal. 27:2054–2067. 2015. View Article : Google Scholar : PubMed/NCBI
34	Ju Ha H and Kim SJ: Association of insulin receptor and syndecan-1 by insulin with activation of ERK I/II in osteoblast-like UMR-106 cells. J Recept Signal Transduct Res. 33:37–40. 2013. View Article : Google Scholar : PubMed/NCBI